| Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab Y Dargaud, A Lienhart, M Janbain, S Le Quellec, N Enjolras, C Negrier Haematologica 103 (4), e181, 2018 | 100 | 2018 |
| Laboratory monitoring in emicizumab-treated persons with hemophilia A J Müller, I Pekrul, B Pötzsch, B Berning, J Oldenburg, M Spannagl Thrombosis and Haemostasis 119 (09), 1384-1393, 2019 | 87 | 2019 |
| Acquired hemophilia A: emerging treatment options M Janbain, CA Leissinger, R Kruse-Jarres Journal of Blood Medicine, 143-150, 2015 | 77 | 2015 |
| Prevalence of diabetes in greater Beirut. KI Hirbli, MA Jambeine, HB Slim, WM Barakat, RJ Habis, ZM Francis Diabetes care 28 (5), 1262-1263, 2005 | 62 | 2005 |
| Bortezomib in plasmablastic lymphoma: a case report and review of the literature NS Saba, D Dang, J Saba, C Cao, M Janbain, B Maalouf, H Safah Oncology Research and Treatment 36 (5), 287-291, 2013 | 56 | 2013 |
| Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors C Chai‐Adisaksopha, SJ Nevitt, ML Simpson, M Janbain, BA Konkle Cochrane Database of Systematic Reviews, 2017 | 35 | 2017 |
| Use of F actor XIII (FXIII) concentrate in patients with congenital FXIII deficiency undergoing surgical procedures M Janbain, DJ Nugent, JS Powell, J St‐Louis, VB Frame, CA Leissinger Transfusion 55 (1), 45-50, 2015 | 24 | 2015 |
| Current concepts in the management of stable ischemic heart disease and acute coronary syndrome in patients with hemophilia AY Jabbar, H Baydoun, M Janbain, KC Ferdinand Annals of translational medicine 6 (15), 2018 | 20 | 2018 |
| What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors? M Janbain, S Pipe Hematology 2014, the American Society of Hematology Education Program Book …, 2016 | 11 | 2016 |
| Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study M Janbain, N Enjolras, JC Bordet, R Bolbos, M Brevet, C Leissinger, ... Journal of Thrombosis and Haemostasis 18 (3), 584-592, 2020 | 9 | 2020 |
| Clinical utility of subcutaneous factor VIII replacement therapies in hemophilia A: a review of the evidence Y Dargaud, M Janbain Journal of Blood Medicine, 1031-1036, 2021 | 7 | 2021 |
| Emicizumab for the treatment of acquired hemophilia A: a multicenter US case series JN Poston, K Al-Banaa, A von Drygalski, AD Parnes, CE Walsh, JF Wu, ... Blood 138, 496, 2021 | 7 | 2021 |
| Managing Pregnant Women with Hemophilia and von Willebrand Disease: How Do We Provide Optimum Care and Prevent Complications? M Janbain, P Kouides International Journal of Women's Health, 1307-1313, 2022 | 4 | 2022 |
| Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study M Janbain, N Enjolras, R Bolbos, M Brevet, JC Bordet, Y Dargaud Haemophilia 27 (6), 1002-1006, 2021 | 4 | 2021 |
| Cancer of the Indiana pouch: a case report and review of the literature N Saba, J Saba, M Janbain, C Bitar, A Lipsky, M Blaya Clinical Genitourinary Cancer 11 (4), e30-e34, 2013 | 4 | 2013 |
| Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A M Sanabria, MTÁ Román, G Castaman, M Janbain, T Matsushita, K Meijer, ... BMJ open 11 (9), e044997, 2021 | 3 | 2021 |
| Interim analyses of the multinational real‐world prospective cohort HEM‐POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A MT Reding, MT Álvarez‐Román, G Castaman, M Janbain, T Matsushita, ... European Journal of Haematology 112 (2), 286-295, 2024 | 2 | 2024 |
| Su1705 Paracentesis Within 12 Hours of Admission Improves Outcomes in Patients With Cirrhosis B Abusneineh, S Garg, M Janbain, P Davitkov, Y Falck-Ytter Gastroenterology 5 (144), S-1001, 2013 | 2 | 2013 |
| Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days … MT Reding, MT Alvarez Roman, M Sanabria, G Castaman, M Janbain, ... Blood 140 (Supplement 1), 5612-5614, 2022 | 1 | 2022 |
| Eptacog beta efficacy in treating mild or moderate bleeds in target joints of individuals with hemophilia A or B and inhibitors in PERSEPT 1 MT Reding, ME Mancuso, S Acharya, S Ahuja, MT Álvarez-Román, ... Blood 140 (Supplement 1), 5597-5599, 2022 | 1 | 2022 |
